Androgen receptor determination in breast cancer: A comparison of the dextran-coated charcoal method and quantitative immunohistochemical analysis

Applied Immunohistochemistry and Molecular Morphology

Volumn 16, Issue 4, 2008, Pages 362-370

  Soiland, Håvard ^a   Skaland, Ivar ^b   Van Diermen, Bianca ^b   Janssen, Emiel A M ^b   Körner, Hartwig ^a   Varhaug, Jan Erik ^a,c   Soreide, Jon Arne ^a   Baak, Jan P A ^a,d,e  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c Department of Surgical Sciences ^*

^d UNIVERSITY OF BERGEN   (Norway)

^e VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Androgen receptor; Breast cancer; Immunohistochemistry; Intratumor heterogeneity; Tissue microarray; Whole sections

Indexed keywords

ANDROGEN RECEPTOR; CHARCOAL; DEXTRAN; AR PROTEIN, HUMAN; DIAGNOSTIC AGENT; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CELL; COMPUTER SIMULATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TISSUE MICROARRAY; BREAST TUMOR; CHEMISTRY; COMPARATIVE STUDY; IMMUNOLOGY; METABOLISM; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CHARCOAL; DEXTRANS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; RECEPTORS, ANDROGEN; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 48949093900     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e31815b9c92     Document Type: Article

References (39)

1. Veronesi U, Boyle P, Goldhirsch A, et al. Breast cancer. Lancet. 2005;365:1727-1741.
2. Osborne CK, Schiff R. Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol. 2005;23: 1616-1622.
3. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med. 2006;354:270-282.
4. Osborne CK, Shou J, Massarweh S, et al. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res. 2005;11:865s-870s.
5. Dowsett M, Houghton J, Iden C, et al. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol. 2006;17:818-826.
6. Søreide Ja, Lea Oa, Varhaug JE, et al. androgen receptors in operable breast cancer: relation to other steroid hormone receptors, correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treatment. Eur J Surg Oncol. 1992;18:112-118.
7. Lea Oa, Kvinnsland S, Thorsen T, et al. Improved measurement of androgen receptors in human breast cancer. Cancer Res.1989;49: 7162-7167.
8. Rody a, Diallo R, Poremba C, et al. androgen receptor expression in ductal carcinoma in situ of the breast: not a helpful marker for classification such as estrogen receptor alpha and progesterone receptor. Appl Immunohistochem Mol Morphol. 2005;13:25-29.
9. Moe RE, anderson BO. androgens and androgen receptors: a clinically neglected sector in breast cancer biology. J Surg Oncol. 2007;95:437-439.
10. Macedo LF, Guo Z, Tilghman SL, et al. Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole. Cancer Res. 2006;66:7775-7782.
11. Kuenen-Boumeester V, Van der Kwast TH, van Putten WL, et al. Immunohistochemical determination of androgen receptors in relation to oestrogen and progesterone receptors in female breast cancer. Int J Cancer. 1992;52:581-584.
12. Kononen J, Bubendorf L, Kallioniemi a, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4:844-847.
13. Kallioniemi OP, Wagner U, Kononen J, et al. Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet. 2001;10:657-662.
14. Torhorst J, Bucher C, Kononen J, et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol. 2001;159:2249-2256.
15. Sauter G, Mirlacher M. Tissue microarrays for predictive molecular pathology. J Clin Pathol. 2002;55:575-576.
16. Tavassoli Fa, Devilee P. World Health Organization Classification of Tumours. Pathology and Genetics: Tumours of the Breast and Female Genital Organs. Lyon, France: IaRC Press; 2003:9-112.
17. Sobin LH, Witterkind C. International Union Classification of Cancer (UICC). TNM Classifications of Malignant Tumors. 6th ed. Hoboyen, New Jersey: John Wiley & Sons; 2002.
18. Janssen EAM, Søiland H, Skaland I, et al. Comparing the prognostic value of PTEN and akt expression with the mitotic activity index in adjuvant chemotherapy treated node-negative breast cancer patients aged <55 years. Cell Oncol. 2007;29: 25-35.
19. Fleege JC, van Diest PJ, Baak JP. Systematic random sampling for selective interactive nuclear morphometry in breast cancer sections. Refinement and multiobserver evaluation. Anal Quant Cytol Histol. 1993;15:281-289.
20. Gundersen HJ, Osterby R. Optimizing sampling efficiency of stereological studies in biology: or "do more less well!" J Microsc. 1981;121:65-73.
21. Bol MG, Baak JP, de Bruin PC, et al. Improved objectivity of grading of T(A,1) transitional cell carcinomas of the urinary bladder by quantitative nuclear and proliferation related features. J Clin Pathol. 2001;54:854-859.
22. Moch H, Schraml P, Bubendorf L, et al. High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Am J Pathol. 1999;154: 981-986.
23. Schraml P, Bucher C, Bissig H, et al. Cyclin E overexpression and amplification in human tumours. J Pathol. 2003;200:375-382.
24. Polkowski W, Meijer GA, Baak JP, et al. Reproducibility of p53 and Ki-67 immunoquantitation in Barrett's esophagus. Anal Quant Cytol Histol. 1997;19:246-254.
25. Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer. Cancer. 2007;109:25-32.
26. Carreno G, Del Casar JM, Corte MD, et al. Local recurrence after mastectomy for breast cancer: analysis of clinicopathological, biological and prognostic characteristics. Breast Cancer Res Treat. 2007;102:61-73.
27. Honma N, Takubo K, akiyama F, et al. Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast. Histopathology. 2005;47:195-201.
28. Schippinger W, Regitnig P, Dandachi N, et al. Evaluation of the prognostic significance of androgen receptor expression in meta-static breast cancer. Virchows Arch. 2006;449:24-30.
29. Hardin C, Pommier R, Calhoun K, et al. A new hormonal therapy for estrogen receptor-negative breast cancer. World J Surg. 2007;31: 1041-1046.
30. Ando S, De amicis F, Rago V, et al. Breast cancer: from estrogen to androgen receptor. Mol Cell Endocrinol. 2002;193:121-128.
31. Davis BW, Zava DT, Locher GW, et al. Receptor heterogeneity of human breast cancer as measured by multiple intratumoral assays of estrogen and progesterone receptor. Eur J Cancer Clin Oncol. 1984;20:375-382.
32. Locher GW, Davis B, Zava DT, et al. Intratumoral regional differences in hormone receptor status of breast cancer. Geburtshilfe Frauenheilkd. 1984;44:304-306.
33. Langley RR, Fidler IJ. Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis. Endocr Rev. 2007;28:297-321.
34. Stockholm D, Benchaouir R, Picot J, et al. The origin of phenotypic heterogeneity in a clonal cell population in vitro. PLoS ONE. 2007;2:e394.
35. Zhang D, Salto-Tellez M, Putti TC, et al. Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer. Mod Pathol. 2003;16:79-84.
36. Henriksen KL, Rasmussen BB, Lykkesfeldt AE, et al. Semiquantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays. J Clin Pathol. 2007;60:397-404.
37. Baak JP, van Diest PJ, Voorhorst FJ, et al. Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years. J Clin Oncol. 2005;23:5993-6001.
38. Skaland I, Janssen EAM, Gudlaugsson E, et al. Phosphohistone H3 expression has much stronger prognostic value than classical prognosticators in lymph node-negative breast cancer patients. Mod Pathol. 2007. [Epub ahead of print]. PMID: 17917671.
39. Holst F, Stahl PR, Ruiz C, et al. Estrogen receptor alfa (ESR1) gene amplification is frequent in breast cancer. Nat Genet. 2007;39: 655-660.